Company intelligence / Profile preview

WearLinq

San Francisco, California, United Stateswearlinq.com ↗

Ownership: Private
Development stage: Commercial

Overview

WearLinq’s eWave device received FDA 510(k) clearance at the end of 2022. The company has begun commercializing the product and expanding access through acquisition of AMI Cardiac Monitoring. The device offers continuous multi-lead ECG monitoring with high diagnostic clarity and real-time data transmission to healthcare providers. Early clinical adoption focuses on improving arrhythmia detection and patient compliance[3][6].

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Physiological Monitoring

Partnerships

Angel investors from iRhythm and AliveCor participated in early funding; no major pharma/biotech partnerships disclosed

Beyond the preview

Go deeper on WearLinq.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WearLinq.

Explore the full profile